DJ Transaction in own shares
Arix Bioscience PLC (ARIX)
Transaction in own shares
22-March-2021 / 17:57 GMT/BST
Dissemination of a Regulatory Announcement, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
=----------------------------------------------------------------------------------------------------------------------
Arix Bioscience plc
Transaction in own shares
LONDON, 22 March 2021: Arix Bioscience plc ("Arix" or "the Company"), a global venture capital company focused on
investing in and building breakthrough biotech companies, today announces that it purchased the following number of its
ordinary shares of 0.001 pence each on the London Stock Exchange from Jefferies International Limited as part of a
buyback programme announced on 22 March 2021.
Date of purchase 22 March 2021
Aggregate number of shares purchased 73,000
Highest price paid per share 193.50p
Lowest price paid per share 191.25p
Average price paid per share 193.40p
Arix intends to retain the purchased shares in treasury.
Following settlement of the above purchase, Arix will have 135,536,653 ordinary shares of 0.001 pence each in issue (excluding 73,000 ordinary shares of 0.001 pence each held in treasury). This number represents the total voting rights in Arix and may be used by shareholders as the denominator for the calculations by which they can determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.
In accordance with Article 5(1)(b) of Regulation (EU) No. 596/2014 (as incorporated into UK domestic law by the European Union (Withdrawal) Act 2018), the schedule below contains detailed information of the individual trades made by Jefferies International Limited as part of the buyback programme.
[ENDS]
For more information on Arix, please contact:
Arix Bioscience plc
Charlotte Parry, Head of Investor Relations
+44 (0)20 7290 1072
charlotte@arixbioscience.com
Optimum Strategic Communications
Mary Clark, Supriya Mathur, Shabnam Bashir
+44 (0)20 3922 1906
optimum.arix@optimumcomms.com
About Arix Bioscience plc
Arix Bioscience plc is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting-edge advances in life sciences.
We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com
Transaction Date Transaction Time Volume Price (GBp) Platform Transaction Reference Number 22/03/2021 10:38:55 1,000 191.25 London Stock Exchange 00231310687TRLO0 22/03/2021 10:45:26 10,000 193.00 London Stock Exchange 00231311867TRLO0 22/03/2021 11:45:39 50,000 193.50 London Stock Exchange 00231322254TRLO0 22/03/2021 14:45:32 3,471 193.50 London Stock Exchange 00231362039TRLO0 22/03/2021 14:59:29 314 192.38 London Stock Exchange 00231366401TRLO0 22/03/2021 16:06:52 8,215 193.50 London Stock Exchange 00231392811TRLO0
ISIN: GB00BD045071
Category Code: MSCH
TIDM: ARIX
LEI Code: HQCXNIX43 -----------------------------------------------------------------------------------------------------------------------
ISIN: GB00BD045071 Category Code: POS TIDM: ARIX LEI Code: 213800OVT3AHQCXNIX43 OAM Categories: 2.4. Acquisition or disposal of the issuer's own shares Sequence No.: 95993 EQS News ID: 1177370 End of Announcement EQS News Service =------------------------------------------------------------------------------------
(END) Dow Jones Newswires
March 22, 2021 13:57 ET (17:57 GMT)
